Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02945462
Recruitment Status : Completed
First Posted : October 26, 2016
Last Update Posted : November 16, 2016
Information provided by (Responsible Party):
Saddam Dmour, University of Jordan

Brief Summary:
Recovery of erectile function using bone marrow mesenchymal stem cells (MSCs) after in vitro expansion under restricted culturing conditions.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Biological: autologous mesenchymal stem cells Phase 1

Detailed Description:

Four diabetic male patients ranging from 25-65 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests. Patients with any evidence of untreated hypogonadism, current urinary tract or bladder infection, clinically evident penile anatomical deformities, previous penile implant or penile vascular surgery, uncontrolled hypertension or hypotension, reported unstable Cardiovascular diseases, uncontrolled diabetes (HbA1c > 10%), or primary hyperlipidemia will be excluded. The investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients.

This study was performed:

  1. To test the safety of autologous intracavernous bone marrow mesenchymal stem cells.
  2. To evaluate benefit for the patient concerning recovery of natural erection by performing detailed and specific diagnostic tests prior and post MSCs injection by a team from Jordan University Hospital and Cell Therapy Center in Jordan University.
  3. To study the feasibility, indication criteria and application modalities of Bone marrow mesenchymal stem cells for further wider study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Using Bone Marrow-derived Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction in Diabetic Patients
Study Start Date : September 2013
Actual Primary Completion Date : November 2015
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: autologous mesenchymal stem cells


Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients

Biological: autologous mesenchymal stem cells
Patients will be injected with autologous mesenchymal stem cells, intracavernously

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: six months ]
    Observation of any relevant adverse side effect resulting from the injection. Assessing the safety of autologous Mesenchymal Stem Cells injection

Secondary Outcome Measures :
  1. Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire [ Time Frame: 18 months ]

    Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Sexual Health Inventory for Men/ International Index for Erectile Function/ Erection Hardness Score (SHIM/IIEF/EHS) questionnaire.

    For every patient tests would be performed at baseline and repeated at 1,3, 6,12, and 18 months post-injection.

  2. Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test. [ Time Frame: 6 months ]
    Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Dynamic Infusion Cavernosometry test at baseline and repeated at 6 months post injection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult male patients ranging from 25 to 65 years.
  2. Type 1 or type 2 diabetic patients with a personal history of diabetes ≥ 5 years.
  3. History of chronic erectile dysfunction for at least six months.
  4. HbA1c ≤ 10%.
  5. Baseline International Index of Erectile Function (IIEF) score of < 26.
  6. Not interested or able to use Phosphodiesterase type 5 inhibitor (PDE-5i) drug therapy and willing to forgo these treatments for the first 6 month period following study treatment.
  7. Body mass index between 20 -30.
  8. Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.

Exclusion Criteria:

  1. Untreated hypogonadism or low serum total testosterone < 200 ng/dl.
  2. Current urinary tract or bladder infection.
  3. Any medical evidence of any infectious disease.
  4. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history of priapism.
  5. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.
  6. Current or previous malignancy.
  7. Patients with primary hyperlipidemia.
  8. Use of any non study treatment for erectile dysfunction within 4 weeks of study treatment.
  9. Lack of willingness to continue through 6 months after study treatment.
  10. Any previous penile implant or penile vascular surgery.
  11. Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg).
  12. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.
  13. Bleeding or clotting disorder, use of anticoagulant therapy.
  14. Lab values for complete blood count, prothrombin time/ partial thromboplastin time/international randomized ratio (PT/PTT/INR), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine falling outside the normal lab values.
  15. Systemic autoimmune disorder.
  16. Significant active systemic or localized infection.
  17. Receiving immunosuppressant medications.
  18. HbA1c > 10%.

Layout table for additonal information
Responsible Party: Saddam Dmour, Researcher, University of Jordan Identifier: NCT02945462    
Other Study ID Numbers: EDUJCTC
First Posted: October 26, 2016    Key Record Dates
Last Update Posted: November 16, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders